You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
長江生命科技(00775.HK)股價飆八成 美國附屬黑色素瘤抗原疫苗免疫療法研究初始數據正面
阿思達克 11-06 13:54

長江生命科技(00775.HK)中午公布,旗下美國一間專注於腫瘤免疫學的生物製藥公司Polynoma的黑色素瘤抗原疫苗免疫療法研究初始數據正面,刺激股價午後飆八成,現造0.64元,創逾年新高,成交放量大增至5,487萬股。

長江生命科技表示,Polynoma將於今年11月8日在美國馬里蘭州國家港口舉行的癌症免疫療法學會2019年度年會上,展示其從黑色素瘤抗原疫苗免疫療法研究(其現正進行的研究性黑色素瘤候選疫苗seviprotimut-L第三階段臨床研究)所得的臨床數據。 公司認為,黑色素瘤抗原疫苗免疫療法研究的初始數據令人鼓舞,而且從分析中所得的功效和安全性的確切證據可見,seviprotimut-L有潛力作為局限性黑色素瘤患者輔助性療法的重要新選項。從黑色素瘤抗原疫苗免疫療法研究中獲得的初步數據亦顯示,seviprotimut-L可能是黑色素瘤疫苗療法的一項重要革新,迄今為止尚未有任何疫苗獲批准用於黑色素瘤輔助性療法。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account